247 related articles for article (PubMed ID: 27797294)
1. Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
Piya S; Andreeff M; Borthakur G
Autophagy; 2017 Jan; 13(1):214-215. PubMed ID: 27797294
[TBL] [Abstract][Full Text] [Related]
2. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
Piya S; Kornblau SM; Ruvolo VR; Mu H; Ruvolo PP; McQueen T; Davis RE; Hail N; Kantarjian H; Andreeff M; Borthakur G
Blood; 2016 Sep; 128(9):1260-9. PubMed ID: 27268264
[TBL] [Abstract][Full Text] [Related]
3. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
Carter BZ; Mak PY; Chen Y; Mak DH; Mu H; Jacamo R; Ruvolo V; Arold ST; Ladbury JE; Burks JK; Kornblau S; Andreeff M
Oncotarget; 2016 Apr; 7(15):20054-67. PubMed ID: 26956049
[TBL] [Abstract][Full Text] [Related]
4. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
5. Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells.
Kouzi F; Zibara K; Bourgeais J; Picou F; Gallay N; Brossaud J; Dakik H; Roux B; Hamard S; Le Nail LR; Hleihel R; Foucault A; Ravalet N; Rouleux-Bonnin F; Gouilleux F; Mazurier F; Bene MC; Akl H; Gyan E; Domenech J; El-Sabban M; Herault O
Oncogene; 2020 Feb; 39(6):1198-1212. PubMed ID: 31649334
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy.
Zhang H; Kang J; Liu L; Chen L; Ren S; Tao Y
Aging (Albany NY); 2020 Oct; 12(20):20111-20126. PubMed ID: 33077697
[TBL] [Abstract][Full Text] [Related]
7. An ARC-Regulated IL1β/Cox-2/PGE2/β-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML.
Carter BZ; Mak PY; Wang X; Tao W; Ruvolo V; Mak D; Mu H; Burks JK; Andreeff M
Cancer Res; 2019 Mar; 79(6):1165-1177. PubMed ID: 30674535
[TBL] [Abstract][Full Text] [Related]
8. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
Sumitomo Y; Koya J; Nakazaki K; Kataoka K; Tsuruta-Kishino T; Morita K; Sato T; Kurokawa M
Blood; 2016 Sep; 128(12):1614-24. PubMed ID: 27480114
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5).
Garrido SM; Appelbaum FR; Willman CL; Banker DE
Exp Hematol; 2001 Apr; 29(4):448-57. PubMed ID: 11301185
[TBL] [Abstract][Full Text] [Related]
10. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
[TBL] [Abstract][Full Text] [Related]
11. ATG5 regulates mesenchymal stem cells differentiation and mediates chemosensitivity in acute myeloid leukemia.
Li Y; Jiang Y; Cheng J; Ma J; Li Q; Pang T
Biochem Biophys Res Commun; 2020 Apr; 525(2):398-405. PubMed ID: 32098672
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.
Mak PY; Mak DH; Mu H; Shi Y; Ruvolo P; Ruvolo V; Jacamo R; Burks JK; Wei W; Huang X; Kornblau SM; Andreeff M; Carter BZ
Apoptosis; 2014 Apr; 19(4):698-707. PubMed ID: 24337870
[TBL] [Abstract][Full Text] [Related]
13. Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
Song JH; Kim SH; Kim HJ; Hwang SY; Kim TS
Int J Oncol; 2008 Apr; 32(4):931-6. PubMed ID: 18360721
[TBL] [Abstract][Full Text] [Related]
14. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
Chen P; Huang H; Wu J; Lu R; Wu Y; Jiang X; Yuan Q; Chen Y
Mol Carcinog; 2015 Dec; 54(12):1678-85. PubMed ID: 25408361
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway.
Yuan B; El Dana F; Ly S; Yan Y; Ruvolo V; Shpall EJ; Konopleva M; Andreeff M; Battula VL
PLoS One; 2020; 15(11):e0242809. PubMed ID: 33253299
[TBL] [Abstract][Full Text] [Related]
18. Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Drusbosky L; Gars E; Trujillo A; McGee C; Meacham A; Wise E; Scott EW; Cogle CR
Leuk Res; 2015 Sep; 39(9):984-9. PubMed ID: 26189107
[TBL] [Abstract][Full Text] [Related]
19. Coculture in vitro with endothelial cells induces cytarabine resistance of acute myeloid leukemia cells in a VEGF-A/VEGFR-2 signaling-independent manner.
Okamoto S; Miyano K; Kitakaze K; Kato H; Yamauchi A; Kajikawa M; Itsumi M; Kawai C; Kuribayashi F
Biochem Biophys Res Commun; 2022 Jan; 587():78-84. PubMed ID: 34872003
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]